Strokes still cause death every 3.3 minutes in the United States and are a leading cause of disability. Although the thrombolytic tissue plasminogen activator has been available for the treatment of ischemic stroke since 1996, no neuroprotectant acute stroke treatment strategy to preserve dysfunctional neurons in the ischemic penumbra has shown efficacy in clinical trials. New approaches for th...

BACKGROUND AND PURPOSE Benefit-risk ratios from recombinant tissue plasminogen activator (rtPA) therapy for acute ischemic stroke demonstrate lack of efficacy if intravenous administration is commenced beyond 3 hours of symptom onset. We undertook to enhance therapeutic effectiveness by ensuring equitable access to rtPA for patients affected by acute ischemic stroke within a 20 000 km(2) popula...

Background: The aim of this study was to evaluate whether higher serum levels of insulin-like growth factor-I (IGF-I) in the acute phase of ischemic stroke are associated with less severe strokes and better functional outcome in a period of 12-month follow-up. Methods: From October 2014 to August 2015, patients with the diagnosis of acute ischemic stroke admitted to the stroke unit of Firoozgar...

Ischemic stroke is associated with cardiovascular autonomic nervous system (ANS) disturbances, including reduced heart rate (HR) variability and acute phase neurohumoral activation with elevated stress hormone levels. The impact of HR variability and neurohumoral factors such as natriuretic peptides on the long-term survival of patients with ischemic stroke has not been studied previously. This...

Acute ischemic stroke is a leading cause of death and disability. Treatment efficacy highly time-dependent. Approximately 20% acute ischaemic occurs in the posterior circulation. Clinical presentation circulation subtle. Diagnosis often delayed frequently missed. CT perfusion has improved diagnostic accuracy been integral to guiding therapy patients with anterior stroke. There are limited studi...

BACKGROUND AND PURPOSE Risk factors for acute ischemic stroke following flow-diverter treatment of intracranial aneurysms are poorly understood. Using the International Retrospective Study of Pipeline Embolization Device (IntrePED) registry, we studied demographic, aneurysm, and procedural characteristics associated with postoperative acute ischemic stroke following Pipeline Embolization Device...

everal researchers have reported that CT perfusion studies have been helpful in diagnosing and managing acute ischemic stroke in large numbers of patients. Adding CT perfusion to the imaging protocol improves the accuracy of a stroke diagnosis and is successful in most cases. Incorporating perfusion may even potentially reduce inpatient costs through improvements in management. Research has sho...

BACKGROUND Levels of the cardiac muscle regulatory protein troponin T (cTnT) are frequently elevated in patients with acute ischemic stroke and elevated cTnT predicts poor outcome and mortality. The pathomechanism of troponin release may relate to co-morbid coronary artery disease and myocardial ischemia or, alternatively, to neurogenic cardiac damage due to autonomic activation after acute isc...

Ischemic stroke continues to be one of the most challenging diseases in translational neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for acute ischemic stroke, but its use is limited to the first hours after stroke onset due to an increased risk of hemorrhagic transformation over time resulting in enhanced brain injury. In this review we discuss the role of ma...

Stroke is a leading cause of death and disability worldwide. Intravenous administration of alteplase (rtPA) within 4.5 hours of symptom onset is currently the only approved drug treatment of acute ischemic stroke (AIS). Various forms of neuroprotection have proven effective in animal models of acute ischemia, but their translation into successful therapies in human stroke has so far been unsucc...